OM:SOBIBiotechs
EMA Tryngolza Review And Gamifant Data Reframe Sobi’s Growth Story
EMA validates Sobi’s application to extend Tryngolza (olezarsen) to adults with severe hypertriglyceridemia, supported by pivotal Phase 3 data.
Tryngolza’s extended indication targets patients at risk of acute pancreatitis where existing treatments often fall short.
New Phase 2a data for Gamifant (emapalumab) in IFN-gamma-driven sepsis are presented at ISICEM, covering inflammation-related organ dysfunction and mortality outcomes.
Both updates highlight late stage pipeline progress for...